ALNY
Income statement / Annual
Last year (2025), Alnylam Pharmaceuticals Inc's total revenue was $3.71 B,
an increase of 65.19% from the previous year.
In 2025, Alnylam Pharmaceuticals Inc's net income was $313.75 M.
See Alnylam Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$3.71 B |
$2.25 B |
$1.83 B |
$1.04 B |
$844.29 M |
$492.85 M |
$219.75 M |
$74.91 M |
$89.91 M |
$47.16 M |
| Cost of Revenue |
$677.17 M
|
$323.37 M
|
$310.41 M
|
$168.82 M
|
$140.14 M
|
$78.05 M
|
$25.06 M
|
$1.80 M
|
$13.37 M
|
$0.00
|
| Gross Profit |
$3.04 B
|
$1.92 B
|
$1.52 B
|
$868.60 M
|
$704.14 M
|
$414.80 M
|
$194.69 M
|
$73.11 M
|
$76.55 M
|
$47.16 M
|
| Gross Profit Ratio |
0.82
|
0.86
|
0.83
|
0.84
|
0.83
|
0.84
|
0.89
|
0.98
|
0.85
|
1
|
| Research and Development Expenses |
$1.32 B
|
$1.13 B
|
$1.00 B
|
$883.02 M
|
$792.16 M
|
$654.82 M
|
$655.11 M
|
$505.42 M
|
$390.64 M
|
$382.39 M
|
| General & Administrative Expenses |
$0.00
|
$975.53 M
|
$795.65 M
|
$770.66 M
|
$620.64 M
|
$588.42 M
|
$479.01 M
|
$382.36 M
|
$199.37 M
|
$89.35 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.21 B
|
$975.53 M
|
$795.65 M
|
$770.66 M
|
$620.64 M
|
$588.42 M
|
$479.01 M
|
$382.36 M
|
$199.37 M
|
$89.35 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.05 M
|
$0.00
|
$0.00
|
$4.17 M
|
-$3.02 M
|
$0.00
|
| Operating Expenses |
$2.54 B
|
$2.10 B
|
$1.80 B
|
$1.65 B
|
$1.41 B
|
$1.24 B
|
$1.13 B
|
$887.78 M
|
$590.00 M
|
$471.75 M
|
| Cost And Expenses |
$3.21 B
|
$2.43 B
|
$2.11 B
|
$1.82 B
|
$1.55 B
|
$1.32 B
|
$1.16 B
|
$889.58 M
|
$590.00 M
|
$471.75 M
|
| Interest Income |
$111.47 M
|
$121.99 M
|
$95.56 M
|
$24.81 M
|
$1.58 M
|
$11.81 M
|
$33.45 M
|
$29.26 M
|
$12.24 M
|
$8.31 M
|
| Interest Expense |
$252.63 M
|
$141.86 M
|
$121.22 M
|
$155.97 M
|
$143.02 M
|
$84.50 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$55.66 M
|
$56.67 M
|
$54.05 M
|
$44.47 M
|
$47.57 M
|
$34.77 M
|
$17.18 M
|
$6.44 M
|
$13.37 M
|
$15.13 M
|
| EBITDA |
$557.24 M |
-$178.85 M |
-$258.24 M |
-$926.56 M |
-$661.56 M |
-$736.33 M |
-$868.08 M |
-$754.24 M |
-$488.19 M |
-$409.46 M |
| EBITDA Ratio |
0.15
|
-0.08
|
-0.14
|
-0.89
|
-0.78
|
-1.49
|
-3.95
|
-10.07
|
-5.43
|
-8.68
|
| Operating Income Ratio |
0.14
|
-0.08
|
-0.15
|
-0.76
|
-0.84
|
-1.68
|
-4.27
|
-10.88
|
-5.56
|
-9
|
| Total Other Income/Expenses Net |
-$178.43 M
|
-$200.49 M
|
-$151.34 M
|
-$341.92 M
|
-$143.49 M
|
-$27.16 M
|
$54.18 M
|
$54.00 M
|
$9.21 M
|
$14.48 M
|
| Income Before Tax |
$323.15 M
|
-$377.38 M
|
-$433.52 M
|
-$1.13 B
|
-$852.14 M
|
-$855.60 M
|
-$885.25 M
|
-$760.67 M
|
-$490.87 M
|
-$410.11 M
|
| Income Before Tax Ratio |
0.09
|
-0.17
|
-0.24
|
-1.09
|
-1.01
|
-1.74
|
-4.03
|
-10.15
|
-5.46
|
-8.7
|
| Income Tax Expense |
$9.41 M
|
-$99.22 M
|
$6.73 M
|
$4.16 M
|
$680.00 K
|
$2.68 M
|
$863.00 K
|
$823.00 K
|
$0.00
|
$0.00
|
| Net Income |
$313.75 M
|
-$278.16 M
|
-$440.24 M
|
-$1.13 B
|
-$852.82 M
|
-$858.28 M
|
-$886.12 M
|
-$761.50 M
|
-$490.87 M
|
-$410.11 M
|
| Net Income Ratio |
0.08
|
-0.12
|
-0.24
|
-1.09
|
-1.01
|
-1.74
|
-4.03
|
-10.17
|
-5.46
|
-8.7
|
| EPS |
2.39 |
-2.18 |
-3.52 |
-9.3 |
-7.2 |
-7.46 |
-8.11 |
-7.57 |
-5.42 |
-4.79 |
| EPS Diluted |
2.33 |
-2.18 |
-3.52 |
-9.3 |
-7.2 |
-7.46 |
-8.11 |
-7.57 |
-5.42 |
-4.79 |
| Weighted Average Shares Out |
$131.00 M
|
$127.65 M
|
$124.91 M
|
$121.69 M
|
$118.45 M
|
$114.99 M
|
$109.26 M
|
$100.59 M
|
$90.55 M
|
$85.60 M
|
| Weighted Average Shares Out Diluted |
$134.68 M
|
$127.65 M
|
$124.91 M
|
$121.69 M
|
$118.45 M
|
$114.99 M
|
$109.26 M
|
$100.59 M
|
$90.55 M
|
$85.60 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
